Novel melatonin ligands of Formula I:or pharmaceutically acceptable salts thereof wherein: n is 1 or 2 m is 0, 1 or 2 p is 0, 1, 2, 3, 4, 5, 6, 7 or 8 v is 2 or 3 A is aryl or heteroaryl Z is O, S or NR8 Y is selected from the group consisting of hydrogen, aryl, heteroaryl, C1-C6 alkyl, C3-C6 cycloalkyl, andR is selected from the group consisting of hydrogen, hydroxyl, —OCF3, CF3, C1-C8 alkyl, C1-C8 alkyloxy, C1-C8 alkylthio, halogen and —Z—(CH2)p-A R1 is selected from the group consisting of C1-C4 alkyl, C3-C6 cycloalkyl, CF3, hydroxy-substituted C1-C4 alkyl, hydroxy-substituted C3-C8 cycloalkyl, and NHR5, wherein R5 is C1-C3 alkyl or C3-C6 cycloalkyl R2 is selected from the group consisting of: hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen R3 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen R and R3 may be connected together to form an —O—(CH2)v bridge representing with the carbon atoms to which they are attached a 5- or 6-membered heterocyclic ring system R4 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen R6 is selected from the group consisting of hydrogen and C1-C6 alkyl R7 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkyloxy, OCF3, CF3, hydroxyl, and halogen and R8 is selected from the group consisting of hydrogen and C1-C4 alkyl.
